Thera-SAbDab

IMDEVIMAB

> Structural Summary

Therapeutic	Imdevimab
Target	SARS-CoV-2 Spike RBD
Heavy Chain	QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYAMYWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTAVYYCASGSDYGDYLLVYWGQGTLVTVSS
Light Chain	QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVSNRFSGSKSGNTASLTISGLQSEDEADYYCNSLTSISTWVFGGGTKLTVL
100% seqID Fv Structure	6xdg [Fvs: CA]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	6xdg [Fvs: CA]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (June '19)	TBC
Estimated Status (June '19)	Active
Recorded Developmental Technology	na
INN Year Proposed	2020
INN Year Recommended	None
Companies Involved	TBC
Conditions Approved	na
Conditions Active	SARS-CoV-2 Infection
Conditions Discontinued	na
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]